To evaluate mutation frequency of cdkn2a/b or rb1 in tumor tissues derived by TALEN injection, PCR products harboring each TALEN-targeted locus of genomic DNA were cloned and sequenced. The gene discussed is CDKN2A; the disease is neoplasm.